Albumin is one of the most abundant proteins in the body of mammals: about 40% of its pool
is located in the intravascular space and the remainder is found in the interstitial space. The …

The diagnosis of cardiac ischemia remains a challenge in contemporary emergency
medicine. A blood-borne biomarker is an attractive alternative to cardiac imaging or stress …

First identified in the early 1990s, IMA is produced when ischemia stresses released from
hypoxic heart tissue induce modification of circulating albumin. 5, 6 The amino terminal end …

Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is
currently the most promising biomarker for early detection of ischemia before the onset of …

Myocardial ischemia has become the leading cause of mortality in western countries and
this unfavorable trend is unlikely to reverse in the near future. The events progression …

Systemic sclerosis (SSc) is a connective tissue disease characterized by widespread
vascular lesions and fibrosis of the skin and internal organs. In SSc, vasospasm causes …

Background: Ischemia-modified albumin (IMA) is a new marker of myocardial ischemia,
there is concern that IMA concentrations may be affected by ischemia occurring in tissues …

OBJECTIVES: The aim of this study was to evaluate the association between ischemia-
modified albumin (IMA), lipids and inflammation biomarkers in patients with …

Ischemia-modified albumin (IMA) has been proposed as a biological marker of myocardial
ischemia (1, 2). Exposure to ischemic myocardium modifies circulating albumin at its NH2 …

Background Previous studies have demonstrated that ischemia-modified albumin (IMA) is a
useful marker for the diagnosis of ischemic events. It was also recently demonstrated that …